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Abstract. 
 
Fibroblast growth factor 2 (FGF-2) is a pow-
erful mitogen involved in proliferation, differentiation, 
and survival of various cells including neurons. FGF-2 
expression is translationally regulated; in particular, the 
FGF-2 mRNA contains an internal ribosome entry site 
(IRES) allowing cap-independent translation. Here, we 
have analyzed FGF-2 IRES tissue speciﬁcity ex vivo 
and in vivo by using a dual luciferase bicistronic vector. 
This IRES was active in most transiently transfected 
human and nonhuman cell types, with a higher activity 
in p53 
 
2
 
/
 
2
 
 osteosarcoma and neuroblastoma cell lines. 
Transgenic mice were generated using bicistronic trans-
genes with FGF-2 IRES or encephalomyocarditis virus 
(EMCV) IRES. Measurements of luciferase activity re-
vealed high FGF-2 IRES activity in 11-d-old embryos 
(E11) but not in the placenta; activity was high in the 
heart and brain of E16. FGF-2 IRES activity was low in 
most organs of the adult, but exceptionally high in the 
brain. Such spatiotemporal variations were not ob-
served with the EMCV IRES. These data, demonstrat-
ing the strong tissue speciﬁcity of a mammalian IRES
in vivo, suggest a pivotal role of translational IRES-
dependent activation of FGF-2 expression during em-
bryogenesis and in adult brain. FGF-2 IRES could con-
stitute, thus, a powerful tool for gene transfer in the 
central nervous system.
Key words: central nervous system • development • 
FGF • in vivo • translational control
 
Introduction
 
FGF-2 or bFGF is a prototype member of the ever in-
creasing FGF family that comprises, to date, 22 genes
involved in the control of cell proliferation and differenti-
ation (Nishimura et al., 1999). FGF-2 is a pleiotropic factor
that induces the proliferation of most mesoderm- and neu-
roectoderm-derived cells (Slack and Isaacs, 1994; Bikfalvi
et al., 1997). In vitro, it stimulates endothelial cell growth
and migration; in vivo, it promotes angiogenesis and is
a major tumor angiogenic factor (Kandel et al., 1991).
FGF-2 is also implicated in wound-healing processes (Bik-
falvi et al., 1997; Ortega et al., 1998). It regulates gap junc-
tion communications in astroglial cells (Reuss et al., 1998).
Furthermore, FGF-2 is a neurotrophic factor able to pro-
mote nerve survival and regeneration after central ner-
vous system (CNS)
 
1
 
 injury (Eckenstein, 1994; Houle and
Ye, 1999). Finally, invalidation of the FGF-2 gene in mice
has established its role in controlling the fate, migration,
and differentiation of neuronal cells (Dono et al., 1998;
Ortega et al., 1998; Zhou et al., 1998). The homeostatic
process of vascular tone control by the autonomous ner-
vous system is impaired in these knockout mice (Dono et
al., 1998; Zhou et al., 1998).
Five FGF-2 isoforms are expressed by the FGF-2 mRNA,
resulting from a process of alternative initiation of transla-
tion from five different initiation codons, including four
noncanonical CUGs (Florkiewicz and Sommer, 1989;
Prats et al., 1989; Arnaud et al., 1999). These isoforms
have different cellular localizations and functions (Bugler
et al., 1991; Couderc et al., 1991; Quarto et al., 1991; Bik-
falvi et al., 1995; Arnaud et al., 1999). Their relative abun-
dance varies according to cells and tissues (Coffin et al.,
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1995; Vagner et al., 1996; Bikfalvi et al., 1997). Interest-
ingly, the murine and human FGF-2 isoforms undergo the
same tissue-specific control in mice overexpressing a hu-
man FGF-2 transgene (Coffin et al., 1995), suggesting con-
servation of the regulatory mechanisms between species.
Several cis-acting elements located within the FGF-2
mRNA leader sequence are involved in the control of
FGF-2 translation (Prats et al., 1992). The FGF-2 mRNA,
in particular, contains an internal ribosome entry site
(IRES)
 
 
 
that allows translation via a nonclassical cap-inde-
pendent mechanism (Vagner et al., 1995). This IRES is
constitutively active in transformed cells and could ac-
count for the deregulated expression of CUG1, -2, and
-3–initiated FGF-2 isoforms (HMW FGF-2; Galy et al.,
1999). In contrast, HMW FGF-2 expression in normal hu-
man cultured cells is translationally controlled by cell den-
sity and stress (Vagner et al., 1996). Given the involve-
ment of FGF-2 in cancer and injury repair, such data
suggest a pivotal role of the IRES in the subtle regulation
of FGF-2 expression in vivo.
To test this hypothesis, we analyzed the regulation of
the FGF-2 mRNA IRES ex vivo in transfected cells and in
vivo using transgenic mice. Our strategy was to express a
bicistronic mRNA encoding two different luciferase re-
porter genes, the second being under the control of the hu-
man FGF-2 IRES. IRES activity was determined from the
ratio of second cistron to first cistron expression. Our re-
sults from transfection of various mammalian cell types,
including mouse, human, hamster, bovine, and monkey
cells, showed that the human FGF-2 IRES functions in dif-
ferent species and in all the tested cell types, with greater
efficiency in neuroblastoma and p53 minus osteosarcoma
cells. IRES activity was elevated in the embryo of trans-
genic mice, particularly in the heart and brain. In contrast,
IRES activity in the adult was low in most organs but re-
mained very high in brain. The in vivo specificity of this ac-
tivity contrasted strikingly with the relatively ubiquitous
expression of viral EMCV IRES.
 
Materials and Methods
 
Plasmid Construction
 
The two plasmids pCRHL and pCREL have been described already
(Huez et al., 1998). The two luciferase genes, 
 
Renilla
 
 luciferase (LucR)
and firefly luciferase (LucF), are controlled by the cytomegalovirus pro-
moter (CMV) and separated by either a hairpin or the encephalomyo-
carditis virus (EMCV) IRES, for pCRHL and pCREL, respectively (see
Fig. 1; Huez et al., 1998). The plasmid pCRFL was constructed by replac-
ing the EMCV IRES with the FGF-2 IRES between the two LUC genes.
In this plasmid, the 5
 
9
 
 539 nucleotides of the FGF-2 cDNA are fused to
the LucF coding sequence.
 
Cell Transfection
 
Cell lines were obtained from American Type Culture Collection (ATCC
European Collection of Cell Cultures [ECACC]). NIH 3T3 is a mouse im-
mortalized fibroblast cell line. C2C12 (accession number for ECACC,
91031101) is a mouse muscle myoblast. ABAE is an adult bovine aortic
endothelial primary cell (Couderc et al., 1991). CHO is a Chinese hamster
ovary carcinoma. HeLa (accession number for ATCC, CCL2) is a human
uterus carcinoma of epithelial origin. COS-7 (accession number for
ATCC, CRL 1654) is a monkey kidney cell transformed by SV-40 large T
antigen. Jurkat (accession number for ATCC, TIB-152) is a human acute
T cell leukemia. Skin fibroblast is a primary culture cell from human skin
(Touriol et al., 1999). ECV304 (accession number for ECACC, 92091712)
is a spontaneously transformed human endothelial cell. 293 (accession
number for ATCC, CRL-1573) is a human kidney epithelial cell, trans-
formed with adenovirus 5. SK-Hep-1 (accession number for ATCC, HTB
52) is a human liver adenocarcinoma of endothelial origin; SK-N-AS (ac-
cession number for ECACC, 94092302) and SK-N-BE (accession number
for EACC, 95011815) are human neuroblastoma. Saos2 (accession num-
ber for ATCC, HTB-85) is a p53 
 
2
 
/
 
2
 
 human osteosarcoma of epithelial
origin. Cells were cultivated according to ATCC or ECACC instructions.
The different cell types were transfected with 1 
 
m
 
g of plasmid and Fu-
gene 6 reagent (Boehringer-Roche) in 12-well petri dishes. 48 h after
transfection, cell lysates were prepared for luminescence activity as previ-
ously described (Huez et al., 1998).
 
Generation of Transgenic Mice 
 
Transgenic mice were obtained by injecting fragments containing either
the CMV-LucR-EMCV IRES-LucF or the CMV-LucR-FGF2IRES-LucF
sequences into one of the pronuclei of (C57Bl/6
 
3
 
CBA)
 
2
 
 fertilized eggs
(Brinster et al., 1985). Transgenic embryos and adult mice were identified
by PCR and Southern blot analysis of placenta or tail DNA using a LucF
500-bp-long probe amplified with the LucF-specific oligonucleotides 5
 
9
 
-
CAGTATGAACATTTCGCAGCC-3
 
9
 
 and 5
 
9
 
- CTGAAGGGACTGTA-
AAAACAGC-3
 
9
 
. Stable lines were maintained by successive crosses with
(C57Bl/6
 
3
 
CBA) F1 mice. The transgene copy number was determined by
PhosphorImager scanning of Southern blots.
 
Reverse Transcription and PCR Analysis
 
The cDNAs were synthesized as previously described, using 5 
 
m
 
g of
DNase-treated total RNA (Touriol et al., 1999). The PCR was performed
with the primer couples, 5
 
9
 
-GATTACCAGGGATTTCAGTCG-3
 
9
 
 and
5
 
9
 
-CTGAAGGGACTGTAAAAACAGC-3
 
9
 
, 5
 
9
 
-CCACATATTGAGC-
CAGTAGC-3
 
9 
 
and 5
 
9
 
-CCATGATAATGTTGGACGAC-3
 
9
 
, to amplify
the LucF or LucR DNA sequences, respectively. The PCR reactions were
carried out using 0.3 U of Goldstar 
 
Taq
 
 DNA polymerase (Eurogentec),
in a final volume of 30 
 
m
 
l, with 1 
 
m
 
l of cDNA. The reaction was performed
on a Perkin Elmer apparatus, under the following conditions: 94
 
8
 
C for 3
min, then 25 cycles of 94
 
8
 
C for 30 s, 58
 
8
 
C for 45 s, 72
 
8
 
C for 45 s, and finally
72
 
8
 
C for 5 min. Amplification results (one third of the reactions) were an-
alyzed on 2% agarose gels (Tris-borate/EDTA), followed by ethidium
bromide staining.
 
Luciferase Activity Analysis
 
The two luciferase activities were measured in cell or tissue extracts and
the IRES activity was determined by calculating the LucR/LucF ratios.
The IRES efficiency between different cell types was compared ex vivo by
calibrating the pCRFL ratio (FGF IRES activity) to pCRHL (background
activity without an IRES). For the in vivo analysis, E11 embryos, heart,
limb bud, tail, brain, liver, and placenta of the E16 embryos, and tissue
fragments of the adults were frozen in liquid nitrogen and stored at
 
2
 
80
 
8
 
C. They were homogenized in 200 
 
m
 
l of passive lysis buffer
(Promega) using thurax and centrifuged for 20 min at 4,500 rpm at 4
 
8
 
C.
The supernatant was centrifuged for 15 min at 13,000 rpm at 4
 
8
 
C, and the
last supernatant was used for luminescence dosage (30 
 
m
 
l). LucR and
LucF activities were measured using the Dual Luciferase kit from
Promega.
 
Results
 
FGF-2 IRES Activity Is Optimal in Neuroblastoma and 
Osteosarcoma Cell Lines
 
The bicistronic vector strategy, which was previously used
to demonstrate the existence of the two vascular endothe-
lial growth factor IRESes (Huez et al., 1998), was used
here to test the activity of the FGF-2 IRES in different cell
types. This bicistronic vector expresses two highly sensi-
tive luciferases, LucR and LucF, which are encoded by the
same mRNA under the control of the cytomegalovirus
promoter (Fig. 1). This promoter was chosen because it
had been shown previously to control the strong expres-
sion of reporter genes in tissue-cultured cells and the 
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quasi-ubiquitous (although variable) expression of trans-
genes in transgenic mice (Furth et al., 1991). The FGF-2
mRNA leader sequence (nucleotides 1–539), including the
IRES, was introduced between the LucR and LucF genes
(Fig. 1, pCRFL). LucR, the first cistron, provides the level
of cap-dependent translation. It is expected to reflect the
activity of CMV sequences in the tissues or cells and, thus,
to be proportional to the amount of bicistronic mRNA.
LucF, the second cistron, is expressed in proportion to the
IRES activity. The use of such an assay, based on dual
highly sensitive reporters, allows rapid and concomitant
quantitation of reporter activity. The IRES activity be-
tween different cell types and independently of transfec-
tion efficiency was calibrated by using the vector pCRHL,
which contains a hairpin but no IRES between the two cis-
trons as a control (Fig. 1, pCRHL).
The FGF-2 IRES activity was measured in 14 different
cell types from human, monkey, bovine, hamster, and
mice that were transiently transfected with either pCRFL
or pCRHL vector. As indicated in Fig. 2, the FGF-2 IRES
showed a large spectrum of activity since it was active in
all the different mammalian cell types tested. However, it
was subjected to strong cell type–specific regulation. For
example, a 12-fold factor was observed between the lowest
(HeLa) and the highest values (Saos-2) within the human
cells. Although IRES activation was not directly corre-
lated to cell transformation, the activity in the four non-
cancerous cell lines (3T3, C2C12, ABAE, and skin fibro-
blasts) was low or very low, whereas it was medium or high
in 6/10 transformed cell lines. Within these latter, low ac-
tivity was observed in the Jurkat cell lines of lymphocyte
origin, whereas high activity was observed in SK-N-BE
and SK-N-AS, the two neuroblastoma cell lines. This sug-
gested that the tissue origin of the cell line might be one
parameter conditioning FGF-2 IRES activity.
 
Generation of Transgenic Mice Expressing Bicistronic 
LucR-IRES-LucF Constructs
 
To determine the tissue specificity of the FGF-2 IRES in
the absence of any bias because of cell transformation or
cell culture conditions, we decided to study the expression
of the LucR-FGF2-IRES-LucF construct in vivo. Therefore,
transgenic mice were produced that contained the LucR-
IRES-LucF DNA fragment (see Materials and Methods).
Two independent lines, RFL12 and RFLD, were estab-
lished that contained 28 and 1 copies of the transgene, re-
spectively. Two other transgenic lines that contained a
similar construct with the viral EMCV IRES in place of
FGF-2 IRES (Fig. 1, pCREL) were also produced. Both of
these lines, RELA and RELB, contained 12–15 copies
of the construct (data not shown).
 
FGF-2 IRES Activity Is High in the Embryo, Especially 
in the Heart and Brain
 
Luciferase activities in the transgenic lines were measured
in the whole embryo and placenta for E11 and in various
tissues of the E16 embryo. As shown in Fig. 3 (left), the ac-
tivity of FGF-2 IRES was high in the E11 embryo, whereas
it was low in the placenta of the two RFL transgenic lines.
Such a difference was also observed in the E16 embryo,
where the placenta showed no significant FGF-2 IRES ac-
tivity, whereas IRES was active in several tissues exhibit-
ing the same CMV transcriptional efficiency, such as the
heart and brain (Fig. 3 and Table I). The level of IRES ac-
tivity varied according to the organ: it was hardly detect-
able in the liver; and low in limb bud and tail, regardless of
the high activity of the CMV promoter in these tissues;
and was high in the heart and brain. In contrast, EMCV
IRES activity was high in all the tissues of the two REL
transgenic lines embryos tested, except in the liver of E16
embryos (Fig. 3, right). These data show that FGF-2 IRES
is active in the early embryo, but is strongly regulated in a
tissue-specific manner.
 
In Adult Mice, the FGF-2 IRES Shows Very High 
Brain-specific Activity
 
The activity of FGF-2 IRES was also measured in differ-
ent adult organs. As shown in Fig. 4 and Table I, the IRES
activity variations were exacerbated in comparison with
the data obtained from cell cultures and embryos. The
Figure 1. Schematic repre-
sentation of the bicistronic
LucR-I-LucF vectors. Vector
construction is described in
Materials and Methods. They
contain the CMV promoter
controlling the expression of
a bicistronic LucR-LucF mRNA. A synthetic intron is present 59
of LucR, and a poly(A) site is present 39 of LucF (Huez et al.,
1998). In the pCRFL construct, the complete FGF-2 59 leader
and beginning of coding sequence (up to nucleotide 539) has
been fused to the firefly luciferase open reading frame. In the
pCRHL construct, a hairpin has been introduced between the
two luciferase genes. The pCREL construct contains the EMCV
IRES between the two LUC genes.
Figure 2. Analysis of the FGF-2 IRES activity in transiently
transfected cells. 14 different cell types were transiently trans-
fected with pCRFL or pCRHL DNA. Cells were harvested 48 h
after transfection, and the luciferase activities present in cell ex-
tracts were measured. FGF-2 IRES activity was determined by
calculating the LucF/LucR ratio. To calibrate the data from the
different cell types, the LucF/LucR ratio of pCRFL was divided
by the ratio of the pCRHL negative control. Experiments were
repeated 5–10 times, and the results are expressed as means 6
SEM. The names of the different cell types (described in Materi-
als and Methods) and the histograms values are indicated on the
left. 
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variation in FGF-2 IRES activity between the different or-
gans attained 400-fold, as illustrated by the activities found
in the stomach (0.4 and 1.2 for the lines RFLD and RFL12,
respectively) and in the brain (191 and 454, respectively;
Fig. 4, left). FGF-2 IRES was weakly expressed in most or-
gans, except the testis (up to 40.7) and the brain, where it
presented exceptionally high activity (up to 454). In con-
trast, except for the liver where neither LucR nor LucF ac-
tivity was significantly detected (this could result from
proteolytic activities known to be present in this organ),
the EMCV IRES activity was high in most adult organs
(Fig. 4, right, and Table I). The high activity of FGF2
IRES observed in the brain strongly suggests that this cel-
lular IRES is upregulated in this tissue. To check that the
strong signal observed in the brain was due to IRES activ-
ity and not to any aberrant event, comparative reverse
transcriptase (RT)–PCR was used to measure the relative
levels of LucF and LucR cistrons. We show that the ratio
of LucF RNA/LucR RNA cistrons was similar in all the
organs tested, including the brain, as expected for such bi-
cistronic mRNAs (Fig. 5). In summary, these data indicate
that the FGF-2 IRES is subjected to stringent regulation in
the adult, and that its activity is strongly upregulated in the
brain.
 
Discussion
 
IRESes, which allow cap-independent translation initiation,
have been discovered in several cellular capped mRNAs
during the last few years. The presence of such elements in
capped mRNAs has raised the question of their function
in the regulation of gene expression. This report shows for
the first time that in contrast to the broad-range activity
of a picornavirus IRES, a mammalian IRES, (i.e, human
FGF-2) is highly tissue-specific in vivo. The tissue specific-
ity that we observed is strongly reminiscent of the pro-
posed role of FGF-2 in embryogenesis and the adult CNS
(Eckenstein, 1994; Slack and Isaacs, 1994; Houle and Ye,
1999). These data constitute a new step in our under-
standing of the physiological relevance of cellular mRNA
IRESes.
The analysis of our transgenic mice showed that the hu-
man FGF-2 IRES is particularly active in the embryo
proper at midgestation. At a later stage, its activity is par-
Figure 3. FGF-2 and EMCV
IRESes activities in trans-
genic mice embryos. Em-
bryos from the transgenic
mouse lines were recovered
at 11 and 16 d postcoitum,
and luciferase activities were
measured in different organs
(indicated on the left) as de-
scribed in Materials and
Methods. IRES activities are
represented by histograms
and were measured by calcu-
lating the LucF/LucR ratio
(Table I). The results are
shown for each of the two in-
dependent transgenic lines
expressing one or other bi-
cistronic construct pCRFL
(FGF-2) or pCREL (EMCV),
as means 6 SEM of experiments that were performed 3–10 times. The lines expressing pCRFL (left) are RFLD (gray boxes) and
RFL12 (black boxes). The lines expressing pCREL (right) are RELB (gray boxes) and RELA (black boxes). nd corresponds to experi-
ments giving no detectable LucR activity.
 
Table I. Measurement of Renilla and firefly luciferase 
Activities in Whole Embryo (E11) and in Embryonic (E16) and 
Adult Tissues of Transgenic Mice Lines RFL12 and RELA
 
RFL:
human FGF-2
REL:
EMCV
Embryo
lucR
 
3
 
10
 
2
 
3
 
lucF
 
3
 
10
 
2
 
2
 
lucR
 
3
 
10
 
2
 
3
 
lucF
 
3
 
10
 
2
 
2
 
E11-embryo 39.5 130 12 62
E11-placenta 11.5 1 22.4 102
E16-limb bud 10,400 6,240 22.5 100
E16-heart 56 170 8.6 80
E16-brain 45 270 32.5 225
E16-liver 43 1.3 1.6 0.1
E16-tail 970 450 119 470
E16-placenta 54 8.1 55 190
 
Adult
 
Testis 164 340 1,787 20,550
Ovary 28.5 13.4 13 52
Intestine 81 4.1 45 77.8
Kidney 122 18.3 64 96
Stomach 168 10 300 360
Heart 96 11.5 141 141
Thymus 3.4 1.7 10 50
Tongue 326 65 2,800 19,600
Brain 14 550 3.2 9.6
Muscle 29,000 5,800 109 54.5
Skin 202 33 640 5,880
Liver 20 1.8 nd nd
Lung 2 0.8 13 220
 
This corresponds to representative values of experiments repeated at least three times.
nd, not detected. 
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ticularly high in the brain and persists in the adult. In con-
trast, as observed from transfection experiments, FGF-2
IRES functions in most tissue culture cell types ex vivo.
All this suggests that the IRES-dependent translation of
FGF-2 might be correlated with cell status, as it is func-
tional in actively proliferating cells, embryonic or in vitro
cultured, and extinguished in fully differentiated and qui-
escent cells, except for the CNS. Interestingly, among the
different cell lines tested, the strongest IRES activity is ob-
served in Saos2, a p53 
 
2
 
/
 
2
 
 osteosarcoma cell line. As p53
has been shown to have an inhibitory effect on FGF-2
translation (B. Galy, L. Créancier, C. Zanibellato, A.C.
Prats, and H. Prats, unpublished results), this could indi-
cate that the FGF-2 IRES is not only subjected to activa-
tion, but also to silencing by trans-acting factors. This si-
lencing could be temporarily removed in response to
specific stimuli, such as stress or tissue lesion (Vagner et
al., 1996). An aberrant activation of the FGF-2 IRES
could participate in acquisition and/or maintenance of the
transformed cell status, in concordance with our previous
observations that the HMW FGF-2 isoforms are constitu-
tively expressed in transformed cells while they are regu-
lated as a function of cell density in subprimary skin fibro-
blasts (Galy et al., 1999).
These data also show that the human FGF-2 IRES activ-
ity is more tissue-specific than species-specific. Indeed, it is
not only active in human cultured cells, but also in ham-
ster, monkey, and mouse cells or tissues, suggesting that
specific cellular trans-acting factors are able to recognize
FGF-2 IRES independently of their origin. This corrobo-
rates previous observations in transgenic mice that ex-
pressed a human FGF-2 cDNA transgene encoding the
different FGF-2 isoforms (Coffin et al., 1995). In those
transgenic animals, the pattern of expression of the differ-
ent human isoforms was highly tissue-specific and corre-
sponded to that of the endogenous FGF-2 isoforms. Inter-
estingly, FGF-2 proteins were observed in tissues such as
the brain where the FGF-2 mRNA could not be detected,
even by RT-PCR (Coffin et al., 1995). This suggests that
the level of translation of the endogenous FGF-2 mRNA
could be upregulated in a few tissues, a hypothesis which is
consistent with our observations of very high IRES activ-
ity in the brain of the IRES FGF-2 transgenic mice.
While the transgenic mice that overexpress FGF-2 (Cof-
fin et al., 1995) provide important information concerning
the pattern of expression of the various FGF-2 isoforms
and its conservation between human and mouse, they can-
not be used to distinguish between cap-dependent and
IRES-dependent translation. The bicistronic vector ap-
Figure 4. FGF-2 and EMCV
IRESes activities in trans-
genic adult mice. Different
organs (indicated on the left)
were prepared from adult
transgenic mice and lu-
ciferase activities were mea-
sured as in Fig. 3. IRES ac-
tivities are represented by
histograms corresponding to
the LucF/LucR activities (see
Table I). The results are
shown for each of the two
independent transgenic lines,
expressing one or other bi-
cistronic construct pCRFL
(FGF-2) or pCREL (EMCV),
as means 6 SEM of experi-
ments that were performed
3–10 times. The lines express-
ing pCRFL (left) are RFLD
(gray boxes) and RFL12
(black boxes). The lines ex-
pressing pCREL (on the
right) are RELB (gray boxes)
and RELA (black boxes). nd
corresponds to experiments
giving no detectable LucR
activity.
Figure 5. Analysis of the bi-
cistronic mRNA in transgenic
tissues by RT-PCR. Total
RNA was extracted from
RFL12 or RELA transgenic
mice brain (B), tongue (To),
or testis (Te), and the level of
LucF and LucR cistrons was
analyzed by RT-PCR (as described in Materials and Methods).
The negative control (C2) corresponds to a PCR experiment
performed using RNA from the brain of a nontransgenic mouse.
The positive control (C1) was performed with an in vitro–tran-
scribed bicistronic RFL mRNA. The bands corresponding to am-
plification of LucR (465 nucleotide) or LucF (366 nucleotide)
cDNAs are indicated by arrows. This experiment enabled us to
check the LucF/LucR ratios at the RNA level in the different or-
gans. 
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proach that we describe in the present study allows us to
enlighten the involvement of the FGF-2 IRES in vivo.
Strikingly, this mechanism of cap-independent translation
is more generally active during embryogenesis than in the
adult, where it is restricted to a few organs. Indeed, we
find high IRES activity in the brain and weaker activity in
the testes, ovaries and lung, whereas all the other tested
organs show no significant IRES activity, even those in
which the CMV promoter is active. In particular, the IRES
is silent in the heart where HMW murine and human
FGF-2 proteins have been detected in FGF-2 transgenic
mice (Coffin et al., 1995), suggesting that a majority of
these isoforms could result from cap-dependent transla-
tion of FGF-2 mRNAs in this organ. The physiological ac-
tivation of FGF-2 IRES observed in the brain, correlated
with the high IRES efficiency in two neuroblastoma cell
lines, suggests the existence of a specific CNS internal en-
try activating factor. The location of the IRES just up-
stream from the CUG1 codon and the observation of
higher HMW FGF-2 synthesis in nervous system cells, in
particular after nerve injury, strongly suggest that IRES
could have an essential role in the brain (Vagner et al.,
1995; Huber et al., 1997; Meisinger and Grothe, 1997).
IRESes constitute powerful tools as they allow the ex-
pression of several genes from the same transcription unit.
Two groups have previously reported that a bicistronic
retroviral vector with the EMCV IRES works stably in
chicken and mouse embryos (Ghattas et al., 1991; Kim et
al., 1992). We show in this study that EMCV IRES func-
tions in a ubiquitous manner not only in the embryos, but
also in most organs of adult transgenic mice. This is in
agreement with a recent report that demonstrates a quasi-
ubiquitous activity of the IRES of another picornavirus,
Theiler’s murine encephalomyelitis virus, in young and
adult transgenic mice (Shaw-Jackson and Michiels, 1999).
In contrast, we demonstrate that the FGF-2 IRES, a cellu-
lar mRNA IRES, shows strong tissue-specific activity.
These observations may be related to another study per-
formed in transgenic flies indicating that the IRES con-
tained in the 5
 
9
 
 untranslated regions of antennapedia and
ultrabithorax exhibited a high degree of developmental
regulation and were not functionally equivalent (Ye et al.,
1997). Furthermore, the IRES of an avian retrovirus
shows considerable activity in multipotent neural cells and
in their glial and neuronal progeny (Derrington et al.,
1999). We hypothesize from these results that retroviral
IRESes and cellular IRESes, which both belong to capped
and polyadenylated transcripts, would present stringent
tissue specificity, whereas the activity spectrum of picor-
navirus IRESes, which in most cases belong to uncapped
mRNA, would be broader.
Finally, the stringent tissue specificity of a given cellular
IRES might be very useful as a biotechnological tool to
drive specific gene expression in a particular tissue. As il-
lustrated in this study, the FGF-2 IRES could be power-
fully used to express neurotrophic factors from multicis-
tronic vectors in CNS regeneration programs.
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